179 related articles for article (PubMed ID: 21072513)
1. 177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi.
Seidl C; Zöckler C; Beck R; Quintanilla-Martinez L; Bruchertseifer F; Senekowitsch-Schmidtke R
Eur J Nucl Med Mol Imaging; 2011 Feb; 38(2):312-22. PubMed ID: 21072513
[TBL] [Abstract][Full Text] [Related]
2. 213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice.
Beck R; Seidl C; Pfost B; Morgenstern A; Bruchertseifer F; Baum H; Schwaiger M; Senekowitsch-Schmidtke R
Cancer Sci; 2007 Aug; 98(8):1215-22. PubMed ID: 17561973
[TBL] [Abstract][Full Text] [Related]
3. Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death.
Seidl C; Schröck H; Seidenschwang S; Beck R; Schmid E; Abend M; Becker KF; Apostolidis C; Nikula TK; Kremmer E; Schwaiger M; Senekowitsch-Schmidtke R
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):274-85. PubMed ID: 15791436
[TBL] [Abstract][Full Text] [Related]
4. Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody.
Bloechl S; Beck R; Seidl C; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7070s-7074s. PubMed ID: 16203804
[TBL] [Abstract][Full Text] [Related]
5. Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging.
Buchhorn HM; Seidl C; Beck R; Saur D; Apostolidis C; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
Eur J Nucl Med Mol Imaging; 2007 Jun; 34(6):841-9. PubMed ID: 17206415
[TBL] [Abstract][Full Text] [Related]
6. Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody.
Huber R; Seidl C; Schmid E; Seidenschwang S; Becker KF; Schuhmacher C; Apostolidis C; Nikula T; Kremmer E; Schwaiger M; Senekowitsch-Schmidtke R
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3922S-8S. PubMed ID: 14506190
[TBL] [Abstract][Full Text] [Related]
7. Differential gene expression triggered by highly cytotoxic alpha-emitter-immunoconjugates in gastric cancer cells.
Seidl C; Port M; Apostolidis C; Bruchertseifer F; Schwaiger M; Senekowitsch-Schmidtke R; Abend M
Invest New Drugs; 2010 Feb; 28(1):49-60. PubMed ID: 19139817
[TBL] [Abstract][Full Text] [Related]
8. Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-concept.
Rondon A; Schmitt S; Briat A; Ty N; Maigne L; Quintana M; Membreno R; Zeglis BM; Navarro-Teulon I; Pouget JP; Chezal JM; Miot-Noirault E; Moreau E; Degoul F
Theranostics; 2019; 9(22):6706-6718. PubMed ID: 31588245
[No Abstract] [Full Text] [Related]
9. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
10. Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate
Maaland AF; Heyerdahl H; O'Shea A; Eiriksdottir B; Pascal V; Andersen JT; Kolstad A; Dahle J
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2311-2321. PubMed ID: 31309259
[TBL] [Abstract][Full Text] [Related]
11. 213Bi-induced death of HSC45-M2 gastric cancer cells is characterized by G2 arrest and up-regulation of genes known to prevent apoptosis but induce necrosis and mitotic catastrophe.
Seidl C; Port M; Gilbertz KP; Morgenstern A; Bruchertseifer F; Schwaiger M; Röper B; Senekowitsch-Schmidtke R; Abend M
Mol Cancer Ther; 2007 Aug; 6(8):2346-59. PubMed ID: 17699730
[TBL] [Abstract][Full Text] [Related]
12. Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy.
Pan MH; Gao DW; Feng J; He J; Seo Y; Tedesco J; Wolodzko JG; Hasegawa BH; Franc BL
Mol Imaging Biol; 2009; 11(3):159-66. PubMed ID: 19034582
[TBL] [Abstract][Full Text] [Related]
13. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
Weber T; Bötticher B; Mier W; Sauter M; Krämer S; Leotta K; Keller A; Schlegelmilch A; Grosse-Hovest L; Jäger D; Haberkorn U; Arndt MA; Krauss J
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):489-98. PubMed ID: 26341366
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis.
Essler M; Gärtner FC; Neff F; Blechert B; Senekowitsch-Schmidtke R; Bruchertseifer F; Morgenstern A; Seidl C
Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):602-12. PubMed ID: 22237842
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
Frost SH; Frayo SL; Miller BW; Orozco JJ; Booth GC; Hylarides MD; Lin Y; Green DJ; Gopal AK; Pagel JM; Bäck TA; Fisher DR; Press OW
PLoS One; 2015; 10(3):e0120561. PubMed ID: 25785845
[TBL] [Abstract][Full Text] [Related]
16. Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer.
Deshayes E; Ladjohounlou R; Le Fur P; Pichard A; Lozza C; Boudousq V; Sevestre S; Jarlier M; Kashani R; Koch J; Sosabowski J; Foster J; Chouin N; Bruchertseifer F; Morgenstern A; Kotzki PO; Navarro-Teulon I; Pouget JP
J Nucl Med; 2018 Aug; 59(8):1234-1242. PubMed ID: 29674421
[TBL] [Abstract][Full Text] [Related]
17. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
18. Targeting angiogenesis for radioimmunotherapy with a
Ehlerding EB; Lacognata S; Jiang D; Ferreira CA; Goel S; Hernandez R; Jeffery JJ; Theuer CP; Cai W
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):123-131. PubMed ID: 28821931
[TBL] [Abstract][Full Text] [Related]
19. Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy.
Garcia-Prada CD; Carmes L; Atis S; Parach A; Bertolet A; Jarlier M; Poty S; Garcia DS; Shin WG; Du Manoir S; Schuemann J; Tillement O; Lux F; Constanzo J; Pouget JP
J Nucl Med; 2023 Dec; 64(12):1956-1964. PubMed ID: 37857502
[TBL] [Abstract][Full Text] [Related]
20. α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.
Heskamp S; Hernandez R; Molkenboer-Kuenen JDM; Essler M; Bruchertseifer F; Morgenstern A; Steenbergen EJ; Cai W; Seidl C; McBride WJ; Goldenberg DM; Boerman OC
J Nucl Med; 2017 Jun; 58(6):926-933. PubMed ID: 28232604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
